FDA approved Augtyro™ for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC.
Bristol Myers Squibb announced that FDA approved Augtyro™ (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). Administered as an oral therapy, Augtyro is a tyrosine kinase inhibitor (TKI) targeting ROS1…